Premium
Effects of chronic chromium picolinate treatment in obese Zucker rats
Author(s) -
Mozaffari Mahmood,
Wimborne Hereward,
Liu Jun Yao,
ElMarakby Ahmed
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.930.4
Subject(s) - medicine , endocrinology , creatinine , urinary system , excretion , glycemic , insulin , blood pressure
Several studies suggest that Cr(Pic)3 confers anti‐inflammatory effects while others have reported a clastogenic effect. Utilizing the severely insulin resistant obese Zucker rats, we tested the hypothesis that chronic Cr(Pic)3 treatment improves glycemic control in association with reductions in markers of oxidative DNA damage (i.e., urinary 8‐hydroxy deoxyguanosine (8‐OHdG)) and inflammation (i.e., urinary monocyte chemoattractant protein‐1 (MCP‐1)). Accordingly, obese Zucker rats were treated with a diet containing 10 mg/kg chromium (as Cr(Pic)3) from 6 weeks to 6 months of age; untreated lean and obese Zucker rats served as controls. The treatment did not improve the glycemic status of obese Zucker rats as indexed by blood glucose, plasma insulin or hemoglobin A1c levels. Similarly, urinary MCP‐1 was not affected by excess dietary intake of Cr(Pic)3. Interestingly, urinary 8‐OHdG excretion was reduced in the treated than untreated obese Zucker rats (p<0.05). However, neither mean arterial pressure nor other indices of renal function (e.g., proteinuria, creatinine clearance or urine osmolality) were affected by chronic treatment with Cr(Pic)3. Taken together, the results suggest that dietary supplementation with Cr(Pic)3 decreases oxidative DNA damage in obese Zucker rats that is not accompanied by changes on blood pressure or glycemic status of the animal. Supported by NIH.